Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02294656 · ClinicalTrials.gov registry record · Phase 1
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide
A Phase 1 study of Cystoid Macular Edema, sponsored by Soll Eye.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT02294656 is a Phase 1 study of Cystoid Macular Edema that has completed, run by Soll Eye. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02294656, a Phase 1 study of Cystoid Macular Edema, has completed, sponsored by Soll Eye.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: * Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) * Any observable fluid on OCT * Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months.
Conditions Studied
Interventions
- DRUG Ranibizumab,
- DRUG Triamcinolone acetonide
Study Locations (1)
Pennsylvania
- Soll Eye - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02294656
The ClinicalTrials.gov registry entry for NCT02294656 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soll Eye, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystoid Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab, is the first listed.
NCT02294656 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02294656 about?
NCT02294656 is a clinical study titled "Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide". This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior...
What is the current status of trial NCT02294656?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2014-11. Estimated completion is 2018-09.
What conditions does trial NCT02294656 study?
This clinical trial studies the following conditions: Cystoid Macular Edema.
What interventions are being tested in trial NCT02294656?
The interventions under investigation include: Ranibizumab, (DRUG), Triamcinolone acetonide (DRUG).
Who is sponsoring clinical trial NCT02294656?
This trial is sponsored by Soll Eye, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02294656 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystoid Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.